Smoldering Multiple Myeloma Clinical Trial
Official title:
Evaluation of the Impact of the Update Multiple Myeloma Criteria on the Natural History of Smoldering Myeloma in Order to Establish New Recommendations About Follow-up and Prognostic Evaluation of Smoldering Myeloma (CARRISMM)
This study is a prospective open label interventional multicenter study evaluating the impact of the update multiple myeloma criteria on the natural history of smoldering myeloma in order to establish new recommendations about follow up and prognostic evaluation of smoldering myeloma.
In 2014, the International Myeloma Working Group (IMWG) proposed a revised classification of multiple myeloma (MM) and smoldering myeloma (SMM). Since the new definition of SMM proposed excludes "ultra-high risk SMM", the evolution profile of SMM will change. Therefore, investigators need to update their knowledge of SMM to optimize the management of patients. This project is expected to describe more precisely the new landscape of SMM. The results will help to establish new recommendations for the standard care of SMM and especially for defining accurate follow-up and risk stratifying. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01222286 -
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
|
Phase 2 | |
| Withdrawn |
NCT00503763 -
Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT02916771 -
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01955395 -
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma
|
N/A | |
| Completed |
NCT01237054 -
Imaging in MGUS, SMM and MM
|
Phase 2 | |
| Completed |
NCT02903381 -
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT03301220 -
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
|
Phase 3 | |
| Active, not recruiting |
NCT03236428 -
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01718899 -
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT00112827 -
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT00099047 -
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
|
Phase 2 | |
| Terminated |
NCT01248455 -
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT03289299 -
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
|
Phase 2 | |
| Not yet recruiting |
NCT06365060 -
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
|
||
| Active, not recruiting |
NCT02415413 -
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01302886 -
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT05841550 -
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06183489 -
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT06383143 -
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
|
||
| Active, not recruiting |
NCT02886065 -
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
|
Phase 1 |